Abstract:
Background: Primary tinnitus is a common problem that impair quality of life. Currently, there is no standard treatment to cured and no studies have been found in Thailand on the results of using EGb 761® in reducing this symptom.
Objectives: Study of the effectiveness of EGb 761® in treating tinnitus compared to
placebo and side effects of EGb 761®.
Materials and Methods: This study was a Randomize, Placebo-controlled, Triple-Blind
clinical trial of 71 patients with primary tinnitus more than 3 months. aged from 20 years.
They visited the Department of Otolaryngology at Burapha University Hospital from July 2022 to May 2024. Divided into 2 groups. 36 patients received treatment with EGb 761® and 35 received placebo. Data were collected using an 11 point-box scale to rate the loudness and annoyance of tinnitus and the severity of the impact that the patient received from tinnitus handicap inventory (THI) before treatment and after the 2nd, 6th, 12th week of treatment.
Results: Patients who received treatment in both the EGb 761® group and the placebo group were significant decreases in loudness and annoyance scores based on the 11 point-box scale and THI scores over the 12 weeks of treatment. scores began to decrease significantly from week 2. When comparing between groups It was found that the annoyance score measured by the 11 point-box scale in the EGb 761® group was significantly lower than the placebo group at week 12, and the THI score in the EGb 761® group was significantly lower than the placebo group. Statistically significant, at weeks 2, 6, and 12, no serious side effects were observed in either group of patients.